加载中
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
常规交易时段
€3.175
+€0.015 · +0.47%
盘中时间采用ET。市场数据可能有所延迟。
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
日内区间
当前€3.175
52周区间
当前€3.175
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
11
估值过高
情绪
44
多空交织
风险
66
高风险
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
日内区间
当前€3.175
52周区间
当前€3.175
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 448.3万 EUR | 919.8万 EUR | 1747.7万 EUR | 1217.9万 EUR | 419.4万 EUR |
| 销货成本 | 279.61万 EUR | 388.11万 EUR | −2.3万 EUR | 99.5万 EUR | 101.7万 EUR |
| 毛利 | 151万 EUR | 919.8万 EUR | 1750万 EUR | 1705.7万 EUR | 419.4万 EUR |
| 研究与开发 | 8360.76万 EUR | 9088万 EUR | 1.1亿 EUR | 6046.9万 EUR | 4845.2万 EUR |
| 销售、一般及管理费用 | 5389.2万 EUR | 1709.9万 EUR | 1560.7万 EUR | 1549.5万 EUR | 1152万 EUR |
| 营业费用 | 1.37亿 EUR | 1.07亿 EUR | 1.2亿 EUR | 7416.7万 EUR | 5630.9万 EUR |
| 利息收入 | 282.88万 EUR | 114.3万 EUR | 94.5万 EUR | 39万 EUR | 5.7万 EUR |
| 利息支出 | 3229.6万 EUR | 1217.8万 EUR | 517.8万 EUR | 70.7万 EUR | 13.8万 EUR |
| 折旧和摊销 | 322.3万 EUR | 519.8万 EUR | 259.9万 EUR | 169.8万 EUR | 92.34万 EUR |
| 营业利润 | −1.31亿 EUR | −9755.8万 EUR | −1.03亿 EUR | −5711万 EUR | −5211.4万 EUR |
| 净利润 | −3.4亿 EUR | −1.84亿 EUR | −1.1亿 EUR | −5427.4万 EUR | −4963.6万 EUR |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
€14.00
上涨空间 340.94%报告持有此股票敞口的交易所交易基金。
Simplify Propel Opportunities ETFSURI99.06万1.30%7606.44万 USD2.82%US$17.18-0.22%
State Street SPDR S&P International Small Cap ETFGWX39.74万0.04%9.08亿 USD0.40%US$45.2037-0.78%
Harbor Health Care ETF (MEDI)MEDI11.29万0.28%4144.63万 USD0.80%US$32.315-0.45%
ActivePassive International Equity ETFAPIE4.37万—11.41亿 USD0.45%US$38.579+0.05%
State Street SPDR Portfolio Europe ETFSPEU2.51万0.00%6.83亿 USD0.07%US$53.07-0.11%Simplify Propel Opportunities ETFSURIState Street SPDR S&P International Small Cap ETFGWXHarbor Health Care ETF (MEDI)MEDIActivePassive International Equity ETFAPIEState Street SPDR Portfolio Europe ETFSPEUAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
